



Technology Brief: Anti-Glut 1 Antibodies as an Anti-cancer Therapy

Docket Number: 07B083

Summary	<ul style="list-style-type: none"> • Cancers utilize glucose as the primary fuel to meet its high energy demands. Glucose uptake is primarily accomplished by the Glut-1 transporter. • Antibodies against Glut-1 can alter glucose transporter function; thereby reducing the influx of glucose into cancer cells, causing tumor cell death. • Evidence shows Glut-1 inhibition makes tumors more vulnerable to chemotherapeutic and other targeted agents.
Features and Benefits	<ul style="list-style-type: none"> • Positive PET scans, standard practice used for cancer diagnosis, correlate to patient Glut-1 levels and activity. • Technology has potential applications in multiple forms of cancer (eg. breast, lung, sarcoma, pancreas, etc). • Works in synergy with existing oncology therapies.
Stage of Development	Dr. George Simon
Inventor	US provisional application filed
Patent Status	<p>Initial findings have been published. Animal model studies underway.</p> <p>"Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines." Rastogi S, Banerjee S, Chellappan S, Simon GR. Cancer Lett. 2007 Nov 18;257(2):244-51. Epub 2007 Oct 1</p>

Contact: Haskell Adler PhD MBA
 Senior Licensing Manager
 Office of Technology Management and Licensing
 H. Lee Moffitt Cancer Center and Research Institute
 12902 Magnolia Drive MRC-TTO
 Tampa, FL 33612
 Email: haskell.adler@moffitt.org
 Telephone: 813-745-6596